Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate

In a new setback for Paris-based Ipsen, the FDA is postponing an adcomm meeting that was set for Oct. 31 to review new information on the company’s previously spurned potential treatment of patients with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder.